



NCCP EXECUTIVE MANAGEMENT TEAM MEETING

Date: Monday 13th March 2023 @ 10.30am via MS teams

Present: R. Ó Laoide (Chair), T. Hanan, P. Heckmann, C. Faul, A. Hill, M. Keane

Apologies: P. Cafferty, F. Murphy (NSS), T. McCarthy, F. Bonas

Invited: H. Burns, M. Cox, A. Deane, C. Duffy, J. Gleeson, B. Kneafsey, C. Mellett, E. O'Toole, T. Flattery

A. PRE	SENTATIO	DNS	
A1	Update	-Skin KPIs (Prof. B. Kneafsey)	
	Prof. Kn	eafsey provided an update on Skin KPIs	B.Kneafsey
A2	High Ris	sk Non-Melanoma Skin Cancer GP Referral Guideline (E. O'Toole)	E. O'Toole
	The Hig	h Risk Non-Melanoma Skin Cancer GP Referral Guideline was discussed and by EMT.	
B. MIN	UTES & I	MATTERS ARISING	
B1	Minutes of the previous meeting		
	The min	utes of the EMT meetings held on 13 th February 2023 were agreed.	
B2	Matters		
	2.	Prostate post-treatment surveillance guideline — query regarding follow-up element. To be discussed with Guideline Group and update to be provided to EMT. Action: Update at next EMT meeting Numbers of schools visited as part of the joint initiative with Marie Keating Foundation regarding cancer prevention — figures to be provided to EMT. Clarification was provided on this post meeting: The Schools' Cancer Awareness Programme is delivered each year by Marie Keating Foundation nurses to approximately 100 secondary schools around Ireland with up to 5,000 students, in addition to wider events such as the Schools Summit and TY annual events in November. NCCP supported the	E. O'Toole
	3.	delivery of this Programme. Surgical Centralisation Action: draft update will be shared at next EMT meeting	P. Cafferty/ R. Ó Laoide
	4.	Proton group update	
		Action: Update will be provided at next EMT meeting.	C.Faul/F. Bonas
C. DIREC	TOR's IT	EMS	
C1	•	Clinical Lead for Cancer Research to be appointed	
	•	Work on RHAs is continuing	
	•	Work is progressing on Accreditation, particularly at European level	
	•	National Director Visit to Waterford – 20 th February 2023	
	DING ITE	NAC .	

D1	NCCP Risk Register (J. Gleeson)	
D1	Minor edits to NCCP Risk Register Process were agreed	
	Risks were identified for further consideration and a risk related to Brexit	
	impact was closed.	
	 Consideration to be given to any new risks that need to be added to the 	
	register.	
	register.	
E1	Cancer Screening (F Murphy)	
	No update provided at this meeting	
E2	Evidence and Quality Hub (E. O'Toole)	
	E. O'Toole provided an overview of the High Risk Non-Melanoma Skin Cancer GP	
F2	Referral Guideline (under Item A2 above)	
E3	Cancer Intelligence (M. Cox) KPI update was circulated in advance of meeting	
	Some improvement in KPIs is noted although resilience in the system	
	remains a challenge.	
	Mitigation measures are in place e.g. extra clinics to help improve	
	timeliness of treatment in those hospitals experiencing particular	
	challenges.	
E4	Public Health, Community Oncology and Prevention/Early Detection (H. Burns)	
E4	Hereditary Cancer Model of Care to be discussed at meeting on 15 th	
	March.	
	Water.	
	Action:	
	Hereditary Model of Care to be shared with National Clinical Advisors NCCP in	H. Burns
	advance of discussion on March 15 th .	
	DDCA manda accessorant to be much listed at access times and them.	
	 BRCA needs assessment to be published at same time as Hereditary Cancer Model of Care. 	
	Cancer Woder of Care.	
E5	Cancer Nursing (T Hanan)	
	 NCCP are working with HSE communications to profile the work of the 	
	Acute Oncology Nursing services in upcoming media articles.	
	 ANP meeting is scheduled for May 2023 	
E6	Surgical Programme (A. Hill)	
	Access to theatres for surgery for cancer patients continues to be	
	prioritised	
	NCIS –	
	 noted that the breast forms are excellent. 	
	 Suggestion to carry out some work on streamlining the process for 	
	administrative staff	
	Action: Breast reconstruction- appropriate resourcing needs to progressed with	
	Acutes and Plastic Surgery Programme, particularly in relation to DIEP (deep	A.Hill/R.Ó Laoide/
	inferior epigastric perforator) breast reconstruction, including for women with	T. McCarthy
	BRCA variants.	
E7	Radiation Oncology (C. Faul)	
	Main issues for radiation oncology services generally continue to be	
	capacity and staffing which are impacting KPIs. Outsourcing is continuing.	
	The Covid management capacity plan will be re-introduced to improve	
	KPIs	
	 Options are being explored to mitigate impact on services Two new Consultants have been appointed 	

	trum manufacture in the contraction of the contract	i .
	Action: L. Mullen to be invited to next EMT meeting to provide an update on Survivorship programme	
		L. Mullen
	Work is underway to streamline survivorship protocols for patients.	
G	AOB Survivorship	
G	AOR	
	n/a	
F	FOR INFORMATION	
	Action: Update will be provided on outcome of meetings at next EMT	P.Cafferty/F. Bonas
LIU	Cancer Networks (F Bolias) Cancer Network meetings have been scheduled	
E10	Cancer Networks (F Bonas)	
	streamlined experience for system users.	
	 across hospital sites. Opportunities for system enhancements were discussed to deliver a more 	
	realised in the management of MDTs; there has been a high adoption rate	
	NCIS system and NCCP team implementing the system. Benefits have been	
	National Clinical Advisors to NCCP provided complimentary feedback on the	
	basis.	
	nationally agreed standardised follow-up which can be modified on a patient	
	There is a follow-up module in NCIS that facilitates the integration of a	
	governance document was agreed.	
	Tumour Specific Datasets – the update to the Tumour Specific Datasets	
	priority.	
	of hospitals looking to implement the tumour conference functionality as a	
	Roll-out is continuing. A number of hospitals are well advanced and a number	
E9	National Cancer Information System (NCIS) – P. Heckmann	
	Roche Field Safety Notice (FSN) re SP142 is on-going	
	Genetics/Genomics (P Heckmann/T McCarthy)	
	the NCCP website.	
	Support documentation for patients and clinicians has been made available on	
	therapy that included a new hormonal agent.	
	mutations (germline and/or somatic) who have progressed following prior	
	patients with metastatic castration-resistant prostate cancer and BRCA1/2-	
	 Cancer Drug Management Programme Olaparib has been approved as monotherapy for the treatment of adult 	
	going on identifying challenges outside of the HSE reimbursement process.	
	established. NCCP are being considered for that working group. Work is on-	
	The Mazars report has been published. An implementation group is being	
	Systemic Therapy Programme	
E8	Systemic Therapy Programme [Medical Oncology/Haemato-oncology] (P. Heckmann/M Keane)	
	 availability of radiotherapy staff Marie Curie Professorship to commence late April 2023 	

NCCP Tumour Conference SOP Guidance document

It was agreed

- To publish the NCCP Tumour Conference SOP Guidance on the NCCP website
- To audit the number of tumour specific guidance documents developed by the NCCP Clinical Leads Groups. A further audit of implementation at hospital level may then be appropriate.

DATE OF NEXT MEETING

Monday 17th April 2023 @ 10.30am